Literature DB >> 29119381

Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.

Jon W Collins1, J Heyward Hull1, Julie B Dumond2.   

Abstract

Sparse tissue sampling with intensive plasma sampling creates a unique data analysis problem in determining drug exposure in clinically relevant tissues. Tissue exposure may govern drug efficacy, as many drugs exert their actions in tissues. We compared tissue area-under-the-curve (AUC) generated from bootstrapped noncompartmental analysis (NCA) methods and compartmental nonlinear mixed effect (NLME) modeling. A model of observed data after single-dose tenofovir disoproxil fumarate was used to simulate plasma and tissue concentrations for two destructive tissue sampling schemes. Two groups of 100 data sets with densely-sampled plasma and one tissue sample per individual were created. The bootstrapped NCA (SAS 9.3) used a trapezoidal method to calculate geometric mean tissue AUC per dataset. For NLME, individual post hoc estimates of tissue AUC were determined, and the geometric mean from each dataset calculated. Median normalized prediction error (NPE) and absolute normalized prediction error (ANPE) were calculated for each method from the true values of the modeled concentrations. Both methods produced similar tissue AUC estimates close to true values. Although the NLME-generated AUC estimates had larger NPEs, it had smaller ANPEs. Overall, NLME NPEs showed AUC under-prediction but improved precision and fewer outliers. The bootstrapped NCA method produced more accurate estimates but with some NPEs > 100%. In general, NLME is preferred, as it accommodates less intensive tissue sampling with reasonable results, and provides simulation capabilities for optimizing tissue distribution. However, if the main goal is an accurate AUC for the studied scenario, and relatively intense tissue sampling is feasible, the NCA bootstrap method is a reasonable, and potentially less time-intensive solution.

Entities:  

Keywords:  Bootstrap noncompartmental analysis; Nonlinear mixed effects modeling; Sparse sampling; Tissue pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 29119381      PMCID: PMC5693300          DOI: 10.1007/s10928-017-9554-9

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  29 in total

1.  A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

Authors:  Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

2.  Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Authors:  Gerald S Falchook; Georgina V Long; Razelle Kurzrock; Kevin B Kim; H-Tobias Arkenau; Michael P Brown; Omid Hamid; Jeffrey R Infante; Michael Millward; Anna Pavlick; Melvin T Chin; Steven J O'Day; Samuel C Blackman; C Martin Curtis; Peter Lebowitz; Bo Ma; Daniele Ouellet; Richard F Kefford
Journal:  Clin Cancer Res       Date:  2014-06-23       Impact factor: 12.531

3.  Estimation of confidence intervals for area under the curve from destructively obtained pharmacokinetic data.

Authors:  R C Gagnon; J J Peterson
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

4.  Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies.

Authors:  H Mager; G Göller
Journal:  J Pharm Sci       Date:  1998-03       Impact factor: 3.534

5.  Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.

Authors:  Vincent Jullien; Jean-Marc Tréluyer; Elisabeth Rey; Patrick Jaffray; Anne Krivine; Laurence Moachon; Agnès Lillo-Le Louet; Anne Lescoat; Nicolas Dupin; Dominique Salmon; Gérard Pons; Saïk Urien
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.

Authors:  Peter L Anderson; David V Glidden; Lane R Bushman; Walid Heneine; J Gerardo García-Lerma
Journal:  J Antimicrob Chemother       Date:  2014-05-26       Impact factor: 5.790

7.  Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.

Authors:  Monica Gandhi; David V Glidden; Albert Liu; Peter L Anderson; Howard Horng; Patricia Defechereux; Juan V Guanira; Beatriz Grinsztejn; Suwat Chariyalertsak; Linda-Gail Bekker; Robert M Grant
Journal:  J Infect Dis       Date:  2015-04-20       Impact factor: 5.226

8.  Characterization of AUCs from sparsely sampled populations in toxicology studies.

Authors:  S M Pai; S H Fettner; G Hajian; M N Cayen; V K Batra
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

9.  Estimation of variance for AUC in animal studies.

Authors:  J Yuan
Journal:  J Pharm Sci       Date:  1993-07       Impact factor: 3.534

10.  Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.

Authors:  Angela D M Kashuba; Tanuja N Gengiah; Lise Werner; Kuo-Hsiung Yang; Nicole R White; Quarraisha A Karim; Salim S Abdool Karim
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

View more
  1 in total

Review 1.  Modeling HIV Pre-Exposure Prophylaxis.

Authors:  Thomas Straubinger; Katherine Kay; Robert Bies
Journal:  Front Pharmacol       Date:  2020-01-31       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.